ReNerve (ASX:RNV) signs exclusive distribution deal with Swedish Trading Company covering Hong Kong, Macau and the Greater Bay Area’s 88 million population.
Healthcare Stocks
Austco Healthcare (ASX:AHC) guides to FY26 NPAT growth of 52% to 58% and a 180-hospital US Pulse Mobile rollout in 2026.
Pro Medicus (ASX:PME) has signed a 7-year, A$16m contract with TidalHealth covering the full Visage 7 stack plus cardiology, delivered in the cloud.
Acrux (ASX:ACR) signs A$5.4m Lenzetto licensing amendment with Gedeon Richter, bringing the Estradiol spray to Australia’s short MHT market.
HealthCo (ASX:HCW) has landed a WA Government-backed operator for the Mount Private Hospital, reshaping the risk profile of its Healthscope exposure.
EMVision Medical Devices (ASX:EMV) cleared its Royal Flying Doctor aeromedical study and banked a A$400k MRFF milestone, sharpening the rural stroke case.
Memphasys (ASX:MEM) lands another 1,000 Felix cartridge order from ITL as Qatar’s HMC adds a second console and UAE and Kuwait convert.
Fisher & Paykel Healthcare (ASX:FPH) Lifts Profit 24%
Fisher & Paykel Healthcare (ASX:FPH) shares jumped around 9% on Tuesday after the respiratory care company delivered a full-year result that came in ahead of market expectations. Profit rose 24%, and revenue grew 14% for the year to 31 March 2026. The result was strong, but the…
Noxopharm (ASX:NOX) reports 200-fold TLR8 amplification in human biopsies, backed by a US patent and Nature Immunology paper.
NeuroScientific (ASX:NSB) reported an 80% response rate in fistulising Crohn’s and is launching a second Phase 2 trial to fast-track Australian approval.
